Cooper A J, Scott M F, Rollnick S A
Vestn Otorinolaringol. 2008(5):57-8.
Symptoms of viral and/or streptococcal infectious pharyngitis are of interest in the context of different therapeutic strategies. This study involved 3 family medicine clinics, one emergency service department, and 694 patients. Streptococcal pharyngitis occurred in 24% of the adult patients and in 29% of all the patients. The remaining ones had acute viral pharyngitis or a mixed viral/bacterial infection. Medicamentous therapy given to 98% of the patients included local antibiotics (42%), systemic antibacterial monotherapy (12%), and combined antibiotic therapy (44%). Lysozime-containing preparations (larypront, dequalar, etc.) recommended for pathogenetic therapy had the active ingredient in the form of a dequalinium complex to deliver lysozime to pharyngeal mucosa. The frequency of streptococcal infection in patients with secondary sore throat receiving the combined treatment was twice lower (12%) than in the general group. The strategy of therapy was the same as in primary sore throat.
在不同治疗策略的背景下，病毒性和/或链球菌性感染性咽炎的症状备受关注。本研究涉及3家家庭医学诊所、1个急诊科和694名患者。链球菌性咽炎在24%的成年患者和29%的所有患者中出现。其余患者患有急性病毒性咽炎或混合性病毒/细菌感染。98%的患者接受的药物治疗包括局部抗生素（42%）、全身抗菌单药治疗（12%）和联合抗生素治疗（44%）。推荐用于病因治疗的含溶菌酶制剂（larypront、dequalar等）的活性成分是以地喹氯铵复合物的形式，将溶菌酶输送至咽部黏膜。接受联合治疗的继发性咽痛患者中链球菌感染的频率比普通组低两倍（12%）。治疗策略与原发性咽痛相同。
